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Letter to the Editor 
Chronic benign lymphoproliferation and autoimmune cytopenias are the main features 
requiring treatment in FAS mutant patients with autoimmune lymphoproliferative syndrome 
(ALPS) 1,2. Successful use of the mTOR inhibitor rapamycin has initially been reported in the 
treatment of refractory cytopenia in 3 ALPS-FAS patients3. The remarkable efficacy as a 
second-line agent for this indication was confirmed in a recent prospective study including 
further 9 ALPS-FAS patients4. Here, we analyze aspects of rapamycin therapy that have so 
far not been addressed including first versus second line therapy, comprehensive biomarker 
responses and the consequences of stopping rapamycin by reporting our experience in 28 
ALPS-FAS patients.  
 
We performed a retrospective survey of ALPS patients enrolled into research protocols in 
Paris, France (DC2011-1338) and Freiburg, Germany (DRKS00000298). Patients were 
included if they fulfilled NIH diagnostic criteria of ALPS5 with genetical confirmation, and had 
received rapamycin for >6 months. Lymphoproliferation was defined as enlarged spleen or 
lymphadenopathy (>/= 2 lymph nodes in >/= 2 sites enlarged for >/= 3 months). Autoimmune 
cytopenia required autoantibodies or documented response to immunosuppression. In 
patients not previously treated with steroids or immunosuppressive drugs, rapamycin was 
regarded as first line therapy. IVIG was not considered immunosuppression. Rapamycin was 
initiated at 1-2.8 mg/m2/d aiming for plasma levels of 2-10 ng/ml. Treatment responses were 
evaluated at 6-9 months and at last follow up. Complete remission (CR) was defined as 
normal blood counts with platelets >100,000/mm3, absent splenomegaly (palpable <2cm) 
and lymphadenopathy and cessation of immunosuppression including steroids. Partial 
remission (PR) was defined as persistent symptoms but >/= 50% decrease in spleen size 
and/or in a reference lymph node and cessation of steroids without relapse of cytopenia.  
 
Of 28 patients, 19 had heterozygous germline TNFRSF6 mutations, one had a homozygous 
mutation; 8 had somatic mutations (Suppl. Table 1). Median age at disease onset was 4 (0-
26) years (Table 1). The indication for rapamycin was lymphoproliferation in 8, 
lymphoproliferation and autoimmunity in 18, and autoimmunity in 2 patients. Overall, 19 
patients had autoimmune cytopenia (16 in 1 lineage, mostly AIHA, 2 in 2 lineages, 1 in 3 
lineages). Before rapamycin, 7 patients had no previous therapy, 2 had received IVIG. In 
these 9 patients, rapamycin was considered first-line therapy (Table 1). It was initiated as 
monotherapy in 8 patients and in P21 together with steroids and IVIG. The remaining 19 
patients had received up to 6 lines of previous therapies for a median of 3.7 (0.3-13) years. 
Two patients had undergone hematopoietic stem cell transplantation. Both had disease 
relapses due to graft rejection (P1) and mixed chimerism (P14). In these patients, rapamycin 
was considered second-line therapy (Tabe 1). At initiation of rapamycin, 3/19 had no 
response to previous treatment, 13 were in PR and 3 had responded, but had side effects 
(Table 1). Except for two cases, ongoing therapy was maintained (steroids=9, 
steroids+6MP=2, 6MP=4, AZA=3, MMF=1). Rapamycin was introduced at a median dose of 
2 (1-2.8) mg/m2. After 6-9 months of treatment, 22 patients (79%) were in CR and 6 (21%) in 
PR. Rapamycin add-on therapy led to CR in 94% (17/18). The other immunosuppressive 
drugs were discontinued in all patients within 6 months, except for one with PR (P13). In that 
patient, who had presented with severe AIHA, rapamycin resolved the splenomegaly and 
stabilized, but did not fully control AIHA. Nevertheless, corticosteroids could be terminated. 
First-line rapamycin induced CR in 4 and PR in 5 patients (Table 1, suppl. Fig. 1). The 
incomplete treatment response was associated with documented poor compliance in 2 
patients (P22 and P28). The other 3 PR patients were satisfied with the response achieved 
and no dose escalation or alternative therapies were attempted. Importantly, rapid 
stabilization of cytopenias was achieved among all 5 patients who received rapamycin as 
first line therapy for AIHA or ITP. At last follow up, 26 patients were still on rapamycin. P28 
developed IgG4-related disease while on rapamycin and it was decided to stop treatment, 
P22 stopped because of feeling “unwell” on the medication. Median treatment duration was 
2.8 (0.5-5.6) years. All 23 patients with initial CR maintained CR (Table 1). Rapamycin dose 
was reduced in 14/22 patients where this information was available. At last follow up, serum 
levels were available in 10 patients and CR was maintained in all 6 patients at levels 
between 2-5 ng/ml.  
 
As described3,6, DNT cells rapidly decreased upon rapamycin treatment, but only 7/25 
patients (33%) reached normal percentages (Fig. 1A). IL-10 levels decreased, but remained 
>20 pg/ml in 14/23 patients (61%) (Fig.1C). sFASL decreased, but only 2/28 patients 
reached normal values (Fig. 1D). Significant biomarker decreases were observed in both first 
and second-line treated patients. VitB12 levels remained elevated in 16/23 (69%) patients. 
While 6/19 patients with second line treatment showed a drop in VitB12 levels, 7/19 showed 
an increase (Fig. 1B). All patients with rapamycin first line treatment showed a decrease (Fig. 
1 B). Among 22 patients in CR, two had complete normalization and 5 had close to normal 
values for DNT cells, IL-10 and sFASL, while 15 patients still had elevated biomarkers. 
Biomarker responses were not statistically different between PR and CR patients. Thirteen 
patients experienced mild adverse effects, including mouth ulcers (n=4), mild proteinuria 
(n=2), increased blood pressure (n=2) and transient skin rash, Helicobacter Pylori associated 
gastritis, transient liver enzyme elevation concomitant to herpes zoster and EBV infection in 
one patient each. In 6 patients, rapamycin was temporarily stopped due to incompliance 
(n=3), complete remission (n=2) or elevated blood pressure (n=1). All 6 had rapid relapse of 
lymphoproliferation and two relapsed with autoimmune cytopenias, accompanied by rapid re-
augmentation of biomarkers (Fig. 2A, B). Five patients reinitiated treatment. All had the same 
response as during the first treatment episode (Fig. 2A).  
 
Our results provide novel, practically relevant insights on rapamycin therapy in ALPS-FAS 
based on the pioneering original observations by Teachey et al.3,7. First, we confirm the 
efficacy and safety of rapamycin by reporting 28 additional ALPS-FAS patients, all of whom 
responded to treatment. Our results also confirm the good tolerability within the treatment 
period of up to 6 years. Nevertheless, long-term side effects of rapamycin can be relevant 
and careful monitoring is required. Second, we present the first data on ALPS-FAS patients 
receiving rapamycin as first-line therapy. We were not only able to stop all other treatments 
in patients who had received several lines of prior therapy, but we also achieved excellent 
responses using rapamycin as the first and single agent. This included rapid control of 
cytopenia and lymphoproliferative manifestations. Nevertheless, immediate stabilization of 
autoimmune cytopenia cannot be expected and may require initial concomitant treatment. 
We propose to consider rapamycin as a first-line treatment in ALPS-FAS patients. In 
genetically proven cases, there is a clear biological rationale for rapamycin. 
Lymphoproliferation in ALPS is not just due to an accumulation of DNT cells that cannot die, 
but these cells and their single positive precursor cells8 are highly proliferative in vivo6,9. This 
proliferative activity is associated with hyperactive mTOR signaling6. Blocking proliferative 
activity and induction of apoptosis in DNT cells and their precursors are two non-mutually 
exclusive explanations for the impressive effect of rapamycin on lymphoproliferation6,7. The 
rapid relapse of disease after stopping treatment indicates that the cells giving rise to DNT 
cells are either not fully eliminated or are rapidly regenerated once targeted mTOR inhibition 
is stopped. How rapamycin abrogates autoimmune manifestations remains unclear. Fas 
deficient B cells escape germinal center selection and undergo enhanced somatic 
hypermutation10. Rapamycin could either directly affect B cell signaling or survival and/or it 
could indirectly influence germinal center function by decreasing DNT and IL-10. While 
mTOR inhibition represents targeted molecular treatment for ALPS, this is less clear in 
patients with autoimmunity and lymphoproliferation in the context of other diseases clinically 
resembling ALPS-FAS. Although there are other immunodeficiencies characterized by 
mTOR activation (e.g. activated PI3K delta syndrome11), the rapamycin response in these 
diseases is much more variable4. At present, we therefore advocate first-line rapamycin only 
in ALPS-FAS patients. Third, we present new observations relevant for the guidance of long-
term therapy. Rapamycin levels <5 ng/ml were sufficient to maintain disease control in most 
patients. However, stopping rapamycin was associated with rapid relapse in all cases. Based 
on these observations, we currently start with 2 mg/m2/d and adapt this up to10 ng/ml. Once 
full remission has been achieved, we titrate down to 2-5 ng/ml. Because at least the 
lymphoproliferative manifestations tend to attenuate with age, the necessity of life-long 
treatment remains unclear. Another open issue of long-term treatment is whether rapamycin 
reduces or increases the risk of lymphoma. While biomarkers have proven useful for 
establishing a diagnosis of ALPS-FAS12-14, their value in guiding therapy appears limited. 
Although a significant decrease was observed, CR was accompanied by biomarker 
normalization in no more than a third of the patients. In summary, our results further establish 
rapamycin as an excellent targeted therapy for ALPS-FAS patients and provide support for 
using it as a first-line agent in this disease.  
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 Table 1: Treatment history and rapamycin response of individual patients 
 
 
 
 
Table 1: A) Patients #1-19 were pre-treated as indicated by gray boxes. 1Response to 
treatment: white - no response, gray - partial remission, black - complete remission. „tox“ 
indicates necessity to stop the drug due to side effects. 2Side effects of rapamycin:   white - 
none, gray – moderate, black – requiring stop. Age in years (y) or months (m), 
immunosuppressive treatment (IS), mycophenolate mofetil (MMF), 6-mercaptopurine (6MP), 
azathioprine (AZA), intravenous IgG (IVIG), hematopoietic stem cell transplantation (HSCT), 
anti-CD20 monoclonal antibodies (anti-CD20), rapamycin (rapa), follow up (FU).  
 
  
A) Pretreated patients with second-line rapamycin 
treatment
 
 
           
Patient  1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
age of onset 
 
1m 12m 5y 4m 2m 12y 11y 9y 7m 10m 3.4y 14y 3y 2m 4y 18m 6m 6m 4y 
age start IS 
 
1m 7y 7y 4m 2m 12y 11y 9y 3y 10m 3.4y 14y 3y 2m 4y 18m 4y 16y 8y 
  steroids
 
                                      
  MMF
                                       
  6MP
                                       
  AZA
                                       
  IVIG
                                       
  HSCT
 
 
                                    
  anti-CD20
 
 
         
 
                           
  others
                                       
response
1
 
    
tox 
            
tox 
        
tox  tox  tox 
  
tox  
age start rapa [yrs]
 
13 16 13 6 5 13 14 10 6 1.9 4 14 5 7 5 1.6 6 17 14 
rapa response (6 mo)1
 
                                      
rapa response (last FU)1
 
                                      
rapa side effects
2
 
                                      
 
                   
B) Patients with first-line rapamycin treatment
 
 
         
Patient 20
 
21
 
22
 
23
 
24
 
25
 
26
 
27
 
28
 
 
         
age of onset 
 
3.7y 2.3y 12m 10m 2.0y 8m 22m 2.5y 26y 
 
         
age start rapa  4y 4y 15y 12m 14y 12m 6y 8y 26y 
 
   
rapa response (6 mo)1
 
                  
 
         
rapa response (last FU)1     off           off 
   
 
 
      
rapa side effects
2
 
                
  
 
         
Fig. 1: Biomarker responses at 6 months in patients receiving rapamycin as first-line or 
second-line treatment 
The percentage of DNT cells among CD3+TCRαβ+ lymphocytes (A), the serum levels of 
VitB12 (B), IL-10 (C) and sFASL (D) were determined before rapamycin therapy and 6(-8) 
months after initiation of treatment in patients who received rapamycin as first-line therapy 
(left panels) or after prior immunosuppressive treatment (right panels). Patients with 
complete remission are depicted in black, partial remissions are indicated by open gray 
circles. Analyses were performed using PRISM-software (GraphPad software, San Diego, 
USA). Populations were compared using the Wilcoxon matched-pairs signed rank t-test. 
p<0.05 was considered significant and indicated by asterisk (*p<0.05; **<.01, ***<.001, 
****<.0001).  
 
 
Fig. 2: Effect of treatment discontinuation 
Summary of observations in 6 patients who discontinued rapamycin treatment.  A) Status of 
rapamycin treatment is indicated by [-]/[+]. The spleen size is indicated as follows: - not 
palpable; + palpable but <5 cm; ++ >10 cm or up to umbilicus. Additional lymphadenopathy 
is indicated by °, cytopenia by *. 
B) Percentages of DNT cells (left y-axis, black circles) and sFASL levels (right y-axis, open 
boxes/broken lines) at different stages of therapy. 
 
 
 


 Rapamycin in ALPS  
Suppl. Table 1: Patient cohort 
Pt # Gender Genetic  Mutation Protein level FAS Domain Age of onset [yrs] Clinical presentation 
Status at  last 
follow up 
1 F FAS Htz  Ex 9 c.688-689dup p.Ser230fs Arg Ter12 IC 0,0 LP/AI (bone infiltration) Remission 
2 M FAS Htz  Ex 9 c.709 G>C p.Ala237Pro IC 1,0 LP/AI (pancytopenia) Remission 
3 F FAS Htz Ex 7 c.586 C>T p.Gln196Ter IC 5,0 LP Remission 
4 M FAS Htz Ex 8 c.671 T>G p.Leu224Ter IC 0,3 LP- AI(AIHA) Remission 
5 M FAS Htz Ex 8 c.652-2A>T P.Glu218fsMet Ter3 IC 0,2 LP/AI(AIHA) Remission 
6 M FAS Htz Ex 9 c.794A>G p.Asp265Gly IC 12,0 LP/AI(AIHA) Remission 
7 M FAS Htz Ex 6 c.506-3C>T p.Gly169_Trp189del TM 11,0 AI (ITP) Remission 
8 F FAS Htz Ex 9 c.748C>T p.Arg250Ter IC 9,0 LP Remission 
9 F sFAS  Ex 9 c.812_814del p.Ala271del IC 0,6 LP Remission 
10 F sFAS Ex9 c.768C>G p.Arg250Gly IC 0,8 LP/AI(AIHA) Remission 
11 M sFAS Ex 9 c.815 A>G p.Glu272Gly IC 3,4 LP/AI (ITP) Remission 
12 F FAS Htz Ex 6 c.506-2 A>G p.Gly169_Trp189del TM 14,0 AI (AIHA) Remission 
13 F FAS htz Ex 7 c.613_617del p.Glu205fsProTer4 IC 3,0 LP/AI(AIHA) PR 
14 F FAS hmz Ex 4 c.327T>G p.Cys143Arg EC 0,2 LP/AI(AIHA) Remission 
15 M FAS htz Ex 4 c.410_411del p.Ser137fsTyrTer3  EM 4,0 LP/AI(AIHA) Remission 
16 F FAS Htz Ex 3 c.275_276delCA p.Thr92ArgfsTer13  EC 1,6 LP/AI(AIHA/ITP/NTP) Remission 
17 F sFAS Ex 9 c.712G>T  p.Gly238Ter IC 0,5 LP Remission 
18 M FAS Htz Ex 9 c.779A>G  p.Asp260Gly IC 0,5 LP Remission 
19 M FAS Htz Ex 6 c.536T>G  p.Leu179Arg TM 4,0 LP/AI(AIHA) Remission 
20 M sFAS IVS7 c.652-2A>T  Splice site  IC 3,7 LP/AI(AIHA) PR 
21 M sFAS IVS7 c.652-1G>A  Splice site  IC 2,3 LP/AI(AIHA) Remission 
22 M sFAS Ex 8 c.657_658delAG  p.Val220GlyfsTer6 IC 1,0 LP/AI(ITP) off test 
23 F sFAS Ex 9 c.778G>T  p.Asp260Tyr IC 0,8 LP/AI(Anemia)* Remission 
24 M FAS Htz Ex 4 c.405T>A p.Cys135Ter EC 2,0 LP/AI(AIHA) Remission 
25 F FAS Htz Ex 8 c.676_+1G/C p.Pro217fs IC 0,7 LP PR 
26 M FAS Htz Ex 3 c.471_474delGACA  p.Thr76fs EC 1,8 LP/AI(AIHA) Remission 
27 F FAS Htz Ex 6 c.568G>T p.Val190Leu TM 2,5 LP Remission 
28 M FAS Htz Ex 9 c.792T>G p.Asn264Lys IC 26,0 LP off test, PR with MMF 
 
Suppl. Table 1: Table of patient characteristics, mutations, and clinical manifestations. 
M=male, F=female; IC=intracellular, TM=transmembrane, EC=extracellular; 
LP=lymphoproliferation, AI=autoimmunity, AIHA=autoimmune hemolytic anemia, 
ITP=immune thrombocytopenia, NTP=autoimmune neutropenia, PR=partial remission. 
*P23 suffered from anemia requiring transfusion, but Coombs-test was negative. 
 
 Rapamycin in ALPS  
Suppl. Fig. 1: Clinical rapamycin response at 6 months 
 
 
Suppl. Fig. 1: Clinical response to rapamycin 6 months after treatment initiation. 
Pie-charts show percentages of complete and partial remission of patients receiving 
rapamycin as a first line treatment (left) or second line treatment (right).1The patient 
received steroids concomitantly to rapamycin initiation. 2Two of these five patients had 
documented malcompliance. 
 
 
